WO2002102361A1 - Remedes a des maladies provoquees par une mutation non-sens - Google Patents
Remedes a des maladies provoquees par une mutation non-sens Download PDFInfo
- Publication number
- WO2002102361A1 WO2002102361A1 PCT/JP2002/005914 JP0205914W WO02102361A1 WO 2002102361 A1 WO2002102361 A1 WO 2002102361A1 JP 0205914 W JP0205914 W JP 0205914W WO 02102361 A1 WO02102361 A1 WO 02102361A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dystrophin
- mdx
- mice
- nonsense mutation
- treated
- Prior art date
Links
- 108020004485 Nonsense Codon Proteins 0.000 title claims abstract description 29
- 230000037434 nonsense mutation Effects 0.000 title claims abstract description 27
- 201000010099 disease Diseases 0.000 title claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 108010016626 Dipeptides Proteins 0.000 claims description 8
- 230000003115 biocidal effect Effects 0.000 claims description 8
- 201000006938 muscular dystrophy Diseases 0.000 claims description 7
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 3
- 235000005311 Pandanus odoratissimus Nutrition 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims description 2
- 229920002160 Celluloid Polymers 0.000 claims 1
- 241000806990 Hala Species 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 16
- 102000004169 proteins and genes Human genes 0.000 abstract description 13
- IKHFJPZQZVMLRH-RNFRBKRXSA-N 2-[[[(3r,5r)-3,6-diamino-5-hydroxyhexanoyl]amino]-methylamino]acetic acid Chemical compound OC(=O)CN(C)NC(=O)C[C@H](N)C[C@@H](O)CN IKHFJPZQZVMLRH-RNFRBKRXSA-N 0.000 abstract description 11
- IKHFJPZQZVMLRH-UHFFFAOYSA-N negamycin Natural products OC(=O)CN(C)NC(=O)CC(N)CC(O)CN IKHFJPZQZVMLRH-UHFFFAOYSA-N 0.000 abstract description 11
- 239000003242 anti bacterial agent Substances 0.000 abstract description 7
- 229940088710 antibiotic agent Drugs 0.000 abstract description 7
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 abstract 1
- 229930182566 Gentamicin Natural products 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 51
- 108010069091 Dystrophin Proteins 0.000 description 46
- 102000001039 Dystrophin Human genes 0.000 description 45
- 239000000243 solution Substances 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- 239000003814 drug Substances 0.000 description 15
- 210000003205 muscle Anatomy 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 8
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 7
- 238000003125 immunofluorescent labeling Methods 0.000 description 7
- 210000003141 lower extremity Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 210000001087 myotubule Anatomy 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 5
- 241000186361 Actinobacteria <class> Species 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 239000003729 cation exchange resin Substances 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000002363 skeletal muscle cell Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 3
- 210000000133 brain stem Anatomy 0.000 description 3
- 229920001429 chelating resin Polymers 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 101150046709 dys2 gene Proteins 0.000 description 3
- 229960003699 evans blue Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 208000016361 genetic disease Diseases 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- SYJXFKPQNSDJLI-HKEUSBCWSA-N neamine Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](N)C[C@@H]1N SYJXFKPQNSDJLI-HKEUSBCWSA-N 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- VYCNOBNEBXGHKT-UHFFFAOYSA-N 2-(2-methylhydrazinyl)acetic acid Chemical compound CNNCC(O)=O VYCNOBNEBXGHKT-UHFFFAOYSA-N 0.000 description 2
- 229940117976 5-hydroxylysine Drugs 0.000 description 2
- 241000272875 Ardeidae Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000015178 Hurler syndrome Diseases 0.000 description 2
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 description 2
- 101100465000 Mus musculus Prag1 gene Proteins 0.000 description 2
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108091060545 Nonsense suppressor Proteins 0.000 description 2
- 206010033109 Ototoxicity Diseases 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 231100000262 ototoxicity Toxicity 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 101100290380 Caenorhabditis elegans cel-1 gene Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000709739 Enterobacteria phage f2 Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 238000003619 Marshal aromatic alkylation reaction Methods 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 240000002390 Pandanus odoratissimus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 1
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 101000965899 Simian virus 40 Large T antigen Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 108010039203 Tripeptidyl-Peptidase 1 Proteins 0.000 description 1
- 102100034197 Tripeptidyl-peptidase 1 Human genes 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000011856 Utrophin Human genes 0.000 description 1
- 108010075653 Utrophin Proteins 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 208000024967 X-linked recessive disease Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- YFCUZWYIPBUQBD-ZOWNYOTGSA-N n-[(3s)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide;hydron;chloride Chemical compound Cl.CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 YFCUZWYIPBUQBD-ZOWNYOTGSA-N 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000019362 perlite Nutrition 0.000 description 1
- 239000010451 perlite Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a therapeutic agent for a disease caused by a nonsense mutation, and in particular, to an agent that induces the nonsense mutation to be read through.
- DMD Duchenne muscular dystrophy
- mdx mice which are animal models of DMD, exist.
- This mdx mouse has a nonsense mutation at nucleotide position 3,185 of the dystrophin gene (AA force et al., IAA), resulting in the formation of a stop codon at exon position 23 (Bulfiled, G. et al. , Siller, WG, Wight, PA., Moore, KJ (1989) X chromosome-1 inked muscular dystrophy (mdx) in t he mouse. Proc. Natl. Acad. Sci. USA 81, 1189-1192, Sicinski, P.
- corticosteroids such as prednisone or deflazacotol and azathioprine
- a drug that reduces the use of corticosteroids a drug that reduces the use of corticosteroids.
- the use of corticosteroids has side effects, so the benefit of the drug is limited to short-term use (Granc helli, JA, Pollina,, Hudecki, MS, (2000) Pre-clinical screening of drugs using the drug).
- Duchenne dyst rophy randomized, control led trial of prednisone (18 months) and azothioprine. Neurology 43, 520-527) 0 Therefore, identifying a clinically useful method of suppressing the immature stop mutation in the dystrophin gene is a significant task for a significant number of DMD patients. Will benefit you.
- Genya mycin one of the aminoglycoside antibiotics, reduces translation fidelity and thus nonsense.
- Administration of GM causes suppression of the stop codon during protein translation not only in eukaryotic cells but also in prokaryotic cells.
- GM has already reported on humans related to cystic fibrosis, Hurler's disease and infant neuronal ceroid 1 ipof use inosis, also caused by nonsense mutations. It has also been used in clinical trials with patient cells.
- GM has also been shown to restore dystrophin function in drug-treated mdx mice (Barton-Davis, ER, Cordiner, L., Shoturma, DI, Leiland, SE, Sweeney, H L. (1999) Aminoglycoside antib iotics restore dystrophin function to skeletal muscles of md x mice. J Clin Invest 104, 375-381). And GM treatment is currently in clinical trials for Duchenne and limb girdle muscular dystrophy.
- GM like other aminoglycoside antibiotics, tends to cause many side effects, such as kidney damage and hearing impairment, and prolonged use of one drug may lead to the emergence of drug-resistant bacteria.
- Disclosure of the invention
- aminoglycoside antibiotics such as GM are currently potent drug candidates for the treatment of diseases caused by nonsense mutations, but differ from GM because of their severe side effects Drug candidates with other stop codon read-through activity are required.
- Negamicin methylhydrazinoacetic acid linkage (5-hydroxy-lysine: NM)
- NM methylhydrazinoacetic acid linkage
- a first aspect is a composition for treating a disease caused by a nonsense mutation, which comprises a dipeptide antibiotic.
- the dipeptide antibiotic in the first embodiment is a compound represented by the following formula (1) (molecular weight: 248) or an analog of the compound capable of promoting read-through of nonsense mutation.
- the disease caused by the nonsense mutation is any one of muscular dystrophy, cystic fibrosis, Hala disease, and infant cellophage lipofuscinosis.
- the composition for treating a disease caused by a nonsense mutation of the present invention includes diptide.
- Dipeptide antibiotics do not have the serious side effects of conventional aminoglycoside antibiotics such as genyumycin, and can promote read-through of nonsense mutations. It can be used in combination with genomycin to treat non-sense-induced diseases.
- negamycin analog a compound structurally similar to negamycin (hereinafter referred to as “negamycin analog”) can also be included.
- negamycin analog means that the antibacterial activity is not limited, as long as it is structurally similar to negamycin and has an activity that can promote read-through of nonsense mutation, similarly to negamycin.
- Negamycin can be obtained, for example, from the culture supernatant of actinomycetes strain M890-C2 and strain MF752-NF9 (Hamada, ⁇ ⁇ , Takeuchi, T., Kondo, S. 5 Ikeda, ⁇ ⁇ , Naganawa, H. , Maeda, K., Okami, Y., and Umezawa, H. (1970) A new antibiotic, negamyc in. J Antibiot Tokyo 23, 170-171).
- the “disease caused by nonsense mutation” is not particularly limited as long as it is a disease caused by loss of gene function due to nonsense mutation.
- cystic fibrosis CFTR
- Thalassemia Beta-globin
- gastric cancer APC
- Hemophilia Factor !!, IX
- lung cancer ovarian cancer
- p53 Duchenne type (dystrophin) and limb girdle muscular dystrophy (a-sarcoglycan), obesity (insulin receptor), phenylketo (Phenylalanine hydroxylase) and others (Atkinson, J., and Martin, R.
- the dosage form for administration to a patient is not particularly limited, and may be powders, granules, tablets, capsules, solutions, injections, and the like.
- peptide antibiotics such as negamycin
- pharmaceutically acceptable excipients such as negamycin
- binders such as binders, disintegrants, lubricants
- auxiliary agents such as flavoring agents, solubilizing agents, suspending agents, coating agents, etc. as appropriate be able to.
- FIG. 1 is a photograph showing the presence / absence of dys-oral fin expression and the rate of muscle degeneration in mdx TA muscle with and without negamycin administration. Immunofluorescence and EBD staining were performed as described in Materials and Methods. Panels A, C, and E show the results of immunofluorescence staining using anti-dystrophin antibodies from B10 control mice, untreated mdx mice, and dragon-treated mdx mice, respectively. Panels B, D and F show the EBD staining patterns of B10 control mice, untreated mdx mice and NM treated mdx mice, respectively. The bar is 100 111.
- Figure 2 is a graph showing the percentage of dystrophin expression (immunofluorescence-positive fibers) and degenerated muscle fibers (EBD dye-positive fibers) in TA muscle fibers of antibiotic-treated mice.
- the black bar (shown as “dys” in the figure) indicates the percentage of dystrophin-positive fibers
- the gray bar shown as “EB” in the figure) indicates the percentage of Evans blue-positive fibers .
- "Keio” is Mdx mice (7 weeks old, each 6 animals) in PBS entitled 1.2 X 10- 5 mol / ks / day
- GM is GM
- Fig. 3 is a photograph showing the results of analysis of dystrophin expression using an im- munobing.
- (1) shows dystrophies in B10 control mice (lanes A, B, C), control mdx mice (lanes!), E, F) and NM-administered mdx mice (lanes G, H, I). This shows the result of the sim-nove mouth.
- (2) shows the results of dystrophin imunoblotting in hind limb muscles.
- Lane A mdx mouse treated with bandits
- B sample buffer
- mdx treated with 'NM 100 times A
- D control mdx mouse without NM
- E B10 control mouse.
- FIG. 4 is a photograph showing the results of dystrophin expression in cultured mdx skeletal muscle cells (mdx-sk).
- C and D show the results of dystrophin expression in the cells shown in A and B, respectively.
- A phase contrast micrograph of NM (negamicin 50 ⁇ g / m 1) -treated myotube
- B phase-contrast micrograph of myotube not treated with NM
- C NM (negamicin 50 ig / ml)
- Dissected myotube D NM dystrophine staining of untreated myotubes.
- the bar is 40 m.
- FIG. 5 is a photograph showing the results of immunoprototyping of dystrophin (427 kDa) in cultured mdx skeletal muscle cells (mdx-sk).
- a and B are immunotubes of myotubes treated with a marauder (100 jug / ml) for 7 days, C is an untreated mdx myotube, and D is an immunoblot of C2C12 myotube.
- FIG. 6 is a graph showing changes in body weight of mdx mice upon administration of NM.
- Ne Gamai Shin administration mdx mice (NM1: ⁇ ): negation 1.2X 10- 5 mol / kg dose, NM 10 ( ⁇ ): NM1.2 ⁇ 1 ( ⁇ 4 mol / kg dose, NM50 ( ⁇ ): NM6.0xl0 " 4 mol / kg administration, marauder 100 (X): NM1.2x10 mol / kg administration, control mdx mouse (solid line): NM non-administration.
- FIG. 7 shows the results of the hearing measurement of the antibiotic-administered mice by the brainstem response.
- A, B, and C are the results in mice without antibiotics, mice with NM, and mice with GM, respectively.
- Flask culture C medium (2.0% glucose, 2.0% starch, 2.0% soybean E key scan, 0.5 dry yeast, 353 ⁇ 4 CaC0 35 0.0005% CuS0 4 - 5H 2 0 3 0.0005MnCl 2 - 4 H 2 0, 0.005% ZnS0 4 - 7H 2 0) 60ml has entered the 500ml flask, the Re fifty it its, inoculated with actinomycetes M890- C2 strain was carried out for 4 days with shaking culture (220 r pm) at 28 degrees. The culture was filtered through a pad light (4%), and the filtrate was collected.
- the filtrate was passed through anion column chromatography (Diaion SA10A, 1.5 L, OH form) and eluted with a 0.2N HC1 solution to collect an antibacterial activity fraction against the K-12 strain (every 500 ml). Images, fraction numbers 12 to 16). This active fraction was neutralized with aqueous ammonia and concentrated under reduced pressure to 500 ml. Next, this concentrated solution was passed through a cation exchange resin (Amberlite CG50, 250 ml, NH 4 form), developed with 0.1% aqueous ammonia, and an antibacterial activity fraction against the K-12 strain was collected (every 18 g). Fractions, fraction numbers 31-70). This active fraction was freeze-dried to obtain 32.8 mg of a light brown powder.
- anion column chromatography Diaion SA10A, 1.5 L, OH form
- This powder was resuspended in a buffer solution, passed through a cation exchange resin (Amberlite CG50, 250 ml, NH 4 form) again, and developed with 0.1% aqueous ammonia in the same manner to obtain an antibacterial activity fraction against the K-12 strain. Collected (fraction every 200 g, fraction number 6). This active fraction was freeze-dried to obtain 13.8 mg of a white powder.
- a cation exchange resin Amberlite CG50, 250 ml, NH 4 form
- Jar culture Actinomycetes strain M890-C2 was inoculated into a culture jar containing 5 L of C medium, and shaking culture (300 rpm) was performed at 28 ° C., 5 L / min aeration for 5 days.
- the culture solution was filtered with perlite (4%) in the same manner as after the above flask culture, and the filtrate was subjected to anion column chromatography (Diaion SA10A, 1.5 L, OH form) to collect the active fraction (500 ml). Fractionation, fraction number 9-12). This active fraction was neutralized with ammonia water and concentrated under reduced pressure to 500 ml.
- This concentrate was applied to a cation exchange resin, washed with 1 L of distilled water, developed with 0.1% aqueous ammonia, and the active fraction was collected (2 Fractionation for each OOg, washing fraction and fraction number 1-2). The active fraction was freeze-dried to obtain 4.8 g of a brown powder. This powder was resuspended in a buffer, passed through a cation exchange resin (Amberlite CG50, 250 ml, NH 4 form), developed with 0.1% aqueous ammonia, and the active fraction was collected (every 200 g Fractionation, fraction numbers 15 to: 16). The active fraction was freeze-dried to obtain 27.7 mg of a brown powder. Antibacterial activity was also confirmed for fractions 6 to 9 during the second purification using a cation exchange resin.
- a cation exchange resin Amberlite CG50, 250 ml, NH 4 form
- mdx mouse was prepared as a dystrophin model mouse. NM was dissolved in PBS immediately before injection into mdx mice and filtered using Millipore to avoid degradation during storage in solution. Barton-Davis, E.R., Cordiner, L., Shoturma, D.I., Lei land, S.E., Sweeney, H.L. (1999) Aminoglycoside antibiotics restore dyst rophin function to skeletal muscles of mdx mice .
- dystrophin was detected by immunofluorescence and Evanspl-monostaining. Immunofluorescent staining was performed by the following method using an antibody against the C-terminus of dystrophin. Animals were sacrificed by an excess of ether gas and the tibialis anterior (TA) muscle was removed for immunohistochemistry. Frozen in isopentane for study. After freezing, 7 m cross-section frozen sections were prepared. Frozen sections were pre-plated in a blocking solution for 15 minutes with a solution of 20% poma sera in PBS and then washed three times for 10 minutes with PBS. Next, the sections were incubated at room temperature with a primary antibody (Egret anti-distal fin polyclonal antibody, donated by Dr.
- Evans blue staining was performed by intraperitoneal administration of Evans blue dye (EBD: 0.1% PBS solution of 2% EBD) to all animals 12 hours before sacrifice. Denatured muscle fibers with a permeable membrane are visualized by EBD staining (Matsuda, R., Nishikawa, A., Tanaka, H. (1995) Visualization of dystrophic muscle fibers in mdx mice by vital s taining with Evans Blue: Evidence of apoptosis in dystrophin -deficient muscle. J Biochem 118, 959-964).
- EBD Evans blue dye
- GM Arakawa, M., Nakayama, Y., Hara, T., Shiozuka, M.,
- Negamycin can restore dystrophin in mdx s keletal muscle. Acta Myologica XX, 154-158) The percentage of dystrophine-positive TA muscle fibers was higher in mice treated with NM than in mice treated with NM (Fig. 2) ( Increased membrane permeability (EBD-positive). The results were lower in animals, and were lower in mice treated with GM than in mice treated with GM (Fig. 2).
- the pellet was redissolved in 1 ml of a 1% digitonin solution (0.5 M NaCK, 0.5 M sucrose, 0.1 mM PMSF, 50 mM Tris-HCl, 1 U / ml aprotinin, pH 7.2).
- a 1% digitonin solution 0.5 M NaCK, 0.5 M sucrose, 0.1 mM PMSF, 50 mM Tris-HCl, 1 U / ml aprotinin, pH 7.2.
- the mixture was centrifuged at 14,000 rpm for 5 minutes at 4 ° C. After centrifugation, wash the pellet three times with 0.2% NP-40 in PBS (500 5001), and add sodium dodecyl sulfate (SDS) sample buffer (62.5 DIM Tris-HCl, 2% SDS, 5 mM Boiled in EDTA, 5% 2-mercaptoethanol, 0.1 mM PMSF, 10% glycerol, pH 6.8) for 4 minutes. After boiling, the supernatant was collected and the protein concentration was determined by the microburette method.
- SDS sodium dodecyl sulfate
- the proteins were transferred from the gel to a nitrocellulose membrane (German Sciences) for immuno-mouthing.
- a blocking solution 5% skim milk in 25 mM Tris-HCl [pH 7.4], 137 mM NaCK 2.68 mM KC1, [TBS], 0.05% tween 20: 5% skim milk TBST or PBST
- a dystrophin-specific antibody anti-dystrophin monoclonal antibody DYS3, DYS2, 100-fold diluted [Novocastra, Newcastle, UK] was used.
- the cells were incubated for 1 hour at room temperature with Rofin polyclonal antibody (500-fold dilution). After three washes with 5% skim milk TBST or PBST for 10 minutes, the membrane was diluted 1000-fold or 3000-fold with 5% skim milk TBST with horseradish peroxidase-conjugated secondary antibody. Incubated. Then, the plate was washed three times with TBST or PBST for 30 minutes. The washed membrane is treated with an enzymatic chemiluminescence (ECL) kit (Amersham Armasia Biotech, Tokyo, Japan), and then exposed to X-ray film and Hyperfilm ECL (Amersham Armasia Biotech). By doing so, the electrophoresis pattern of dystrophin was visualized.
- ECL enzymatic chemiluminescence
- Example 3 Effect of NM on dystrophin recovery on immortalized cells (mdx-sk) derived from mdx skeletal muscle cells
- mdx-sk an SV40T immortalized mdx satellite strain
- the establishment of mdx-sk was performed by retrovirus vector containing the cDNA of temperature-sensitive simian virus 40 large T antigen in primary culture of mdx myoblasts collected from mdx mice (donated by Dr. Yunichi Drinkwa). This was done by introducing Retroviruses have been described previously (Morita, S., Kojima, T., Kitamura, II. (2000) PI at-E: an efficient and stable system for transient packaging of retroviruses. Gene Therapy 7).
- differentiation medium solution of 4.0xl (T 4 mol / kg) , after were differentiated for 7 days in antibiotic-free medium.
- C2C12 cells were maintained in growth medium, 38 ° instead of differentiation medium (it was cultured in C 0 2 b Nkyubeta.
- NM can restore dystrophin in the mdx-sk cells established as described above.
- 50 ⁇ g / M of M was added to the differentiation medium of the 7-day-old myotube culture. ml and 100 g / ml were added and the culture was continued for a further 7 days. After culturing (in the presence of NM 50 g / ml), the presence or absence of dystrophin recovery was detected by immunofluorescence staining. The medium was removed from the mdx-sk cells and washed twice with PBS. The cells were fixed with 100% ethanol for 15 minutes, and then treated with 0.5% Triton-X100 in PBS for 10 minutes. Cells were washed three times for 10 minutes with PBS.
- DNase 1 mM phenylmethylsulfonylfluoride [PMSF], 1 / ml N-tosyl -L-phenylalanylchloromethylketone [TPCK] ⁇ 1 ⁇ -g / l N-tosyl-L-risk mouth Romethylketone [TLCK], 200 U / ml abrotinin, 5 mM ethylenediamine tetraacetic acid [EDTA]) Homogenized in 500 ⁇ 1.
- PMSF phenylmethylsulfonylfluoride
- TPCK N-tosyl -L-phenylalanylchloromethylketone
- TLCK 1 ⁇ -g / l N-tosyl-L-risk mouth
- EDTA 5 mM ethylenediamine tetraacetic acid
- Protein A Sepharose ( ⁇ -4 ⁇ (301) (Sigma, Tokyo, Japan) was added, the mixture was incubated at room temperature for another 60 minutes, and the solution was centrifuged at 14,000 rpm for 5 minutes. The cells were washed three times with a 0.2% NP-40 / PBS solution (500 ⁇ l) and boiled in sodium dodecyl sulfate (SDS) buffer for 5 minutes.
- aminoglycoside antibiotics such as GM are associated with severe side effects. Although these antibiotics are used routinely for the treatment of bacterial infections, they often cause nephrotoxicity and ototoxicity. We investigated weight changes and hearing in mice treated with drugs. The title toxicity was determined by measuring the activity.
- mice receiving low doses of NM (1 and 10 times the minimum effective dose) continuously gained weight (NM1, NM in Fig. 6).
- the composition of the present invention is used as a therapeutic agent for diseases caused by nonsense mutations such as muscular dystrophy, cystic fibrosis, and Hurler syndrome, in place of or in combination with genyumycin. , Can be used effectively.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002449950A CA2449950A1 (en) | 2001-06-13 | 2002-06-13 | Agents for treating diseases caused by nonsense mutation |
EP20020738697 EP1402889A1 (en) | 2001-06-13 | 2002-06-13 | Remedies for diseases caused by nonsense mutation |
JP2003504948A JPWO2002102361A1 (ja) | 2001-06-13 | 2002-06-13 | ナンセンス変異に起因した疾患の治療薬 |
IL15931102A IL159311A0 (en) | 2001-06-13 | 2002-06-13 | Remedies for diseases caused by nonsense mutation |
US10/480,735 US20050014835A1 (en) | 2001-06-13 | 2002-06-13 | Agents for Treating Diseases Caused by Nonsense Mutations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29753301P | 2001-06-13 | 2001-06-13 | |
US60/297,533 | 2001-06-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002102361A1 true WO2002102361A1 (fr) | 2002-12-27 |
Family
ID=23146711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/005914 WO2002102361A1 (fr) | 2001-06-13 | 2002-06-13 | Remedes a des maladies provoquees par une mutation non-sens |
Country Status (6)
Country | Link |
---|---|
US (1) | US20050014835A1 (ja) |
EP (1) | EP1402889A1 (ja) |
JP (1) | JPWO2002102361A1 (ja) |
CA (1) | CA2449950A1 (ja) |
IL (1) | IL159311A0 (ja) |
WO (1) | WO2002102361A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008004610A1 (fr) | 2006-07-05 | 2008-01-10 | The University Of Tokyo | Méthode de traitement de maladie génétique provoquée par une mutation non sens |
WO2011096484A1 (ja) | 2010-02-03 | 2011-08-11 | 財団法人微生物化学研究会 | リードスルー誘導剤、及びナンセンス変異型遺伝性疾患治療薬 |
US9371274B2 (en) | 2011-12-01 | 2016-06-21 | The University Of Tokyo | Compound having read-through activity |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8870655B2 (en) * | 2005-08-24 | 2014-10-28 | Nintendo Co., Ltd. | Wireless game controllers |
GB0525492D0 (en) * | 2005-12-15 | 2006-01-25 | Univ Dundee | Filaggrin |
GB0600948D0 (en) | 2006-01-18 | 2006-02-22 | Univ Dundee | Prevention/Treatment Of Ichthyosis Vulgaris, Atopy And Other Disorders |
CN107129440B (zh) * | 2017-06-20 | 2018-12-04 | 上海应用技术大学 | 一种天然产物(+)-负霉素的全合成方法 |
MX2020004647A (es) | 2017-11-02 | 2021-03-25 | Wistar Inst | Métodos de rescate de codones de detención por medio de reasignación genética con arn de transferencia editado anti-codones (ace-trna). |
-
2002
- 2002-06-13 CA CA002449950A patent/CA2449950A1/en not_active Abandoned
- 2002-06-13 EP EP20020738697 patent/EP1402889A1/en not_active Withdrawn
- 2002-06-13 JP JP2003504948A patent/JPWO2002102361A1/ja active Pending
- 2002-06-13 IL IL15931102A patent/IL159311A0/xx unknown
- 2002-06-13 US US10/480,735 patent/US20050014835A1/en not_active Abandoned
- 2002-06-13 WO PCT/JP2002/005914 patent/WO2002102361A1/ja not_active Application Discontinuation
Non-Patent Citations (3)
Title |
---|
UEHARA Y.: "Negamycin inhibits termination of protein synthesis directed by phage f2 RNA in vitro", BIOCHIM. BIOPHYS. ACTA, vol. 374, 1974, pages 82 - 95, XP002957191 * |
UEHARA Y.: "Specific inhibition of the termination process of protein synthesis by negamycin", BIOCHIM. BIOPHYS. ACTA, vol. 442, 1976, pages 251 - 262, XP002957190 * |
UEHARA Y.: "Structure-activity relationships among negamycin analogs", J. ANTIBIOT., vol. 29, 1976, pages 937 - 943, XP002957189 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008004610A1 (fr) | 2006-07-05 | 2008-01-10 | The University Of Tokyo | Méthode de traitement de maladie génétique provoquée par une mutation non sens |
JPWO2008004610A1 (ja) * | 2006-07-05 | 2009-12-03 | 国立大学法人 東京大学 | ナンセンス変異型遺伝性疾患の治療方法 |
WO2011096484A1 (ja) | 2010-02-03 | 2011-08-11 | 財団法人微生物化学研究会 | リードスルー誘導剤、及びナンセンス変異型遺伝性疾患治療薬 |
JP5705136B2 (ja) * | 2010-02-03 | 2015-04-22 | 公益財団法人微生物化学研究会 | リードスルー誘導剤、及びナンセンス変異型遺伝性疾患治療薬 |
US9358246B2 (en) | 2010-02-03 | 2016-06-07 | Microbial Chemistry Research Foundation | Readthrough inducing agent and drug for treating genetic disease caused by nonsense mutation |
US9371274B2 (en) | 2011-12-01 | 2016-06-21 | The University Of Tokyo | Compound having read-through activity |
Also Published As
Publication number | Publication date |
---|---|
IL159311A0 (en) | 2004-06-01 |
JPWO2002102361A1 (ja) | 2004-09-30 |
EP1402889A1 (en) | 2004-03-31 |
US20050014835A1 (en) | 2005-01-20 |
CA2449950A1 (en) | 2002-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Arakawa et al. | Negamycin restores dystrophin expression in skeletal and cardiac muscles of mdx mice | |
Epinette et al. | Mycophenolic acid for psoriasis: a review of pharmacology, long-term efficacy, and safety | |
CA2019974C (en) | Treatment of inflammation | |
JPH09508359A (ja) | 抗グラム陽性細菌学的方法および物質 | |
JPH0223526B2 (ja) | ||
US4916117A (en) | Treatment of inflammation using alpha 1-antichymotrypsin | |
WO2002102361A1 (fr) | Remedes a des maladies provoquees par une mutation non-sens | |
JPH06507382A (ja) | 鎌状赤血球症の治療における分子矯正法 | |
Steinbrecher | Serious infection in an adult due to penicillin-tolerant group B streptococcus | |
JP2000505076A (ja) | エイズ治療用免疫複合体 | |
KR100476782B1 (ko) | 히알루론산수용체결합물질과이의용도 | |
JPH05509309A (ja) | 2―フェニル―1,2―ベンズイソセレナゾール―3(2h)―オンの利用法 | |
CN112138019A (zh) | 环糊精在制备治疗和/或预防多囊肾病药物中的应用 | |
CN110169965B (zh) | 一种化合物在治疗软骨退变性疾病方面的应用 | |
JPH09227386A (ja) | ストレス蛋白質発現増強剤 | |
CN101370524A (zh) | 脂肽组合物 | |
US20240091167A1 (en) | Use of two-dimensional nanomaterial in inhibition of coronavirus | |
Stratigos et al. | Treatment of gonorrhoea with spectinomycin hydrochloride. | |
Zheng et al. | Latest innovations in the treatment of Wilson's disease | |
Peterson et al. | Effects of charge on membrane processing in the proximal nephron | |
WO2006095433A1 (ja) | ウシの消化器疾患治療剤 | |
JPH09500385A (ja) | Tnf誘発病状の治療におけるベンジダミンの使用 | |
US20020068749A1 (en) | Aids remedy | |
JP2694419B2 (ja) | ロタウイルス感染症の予防治療剤 | |
CN113368220A (zh) | 一种ahco组合物及其制剂与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003504948 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 159311 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2449950 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002738697 Country of ref document: EP Ref document number: 2002313217 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2002738697 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10480735 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002738697 Country of ref document: EP |